{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:09:59Z","timestamp":1745467799443,"version":"3.40.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.nrleng.2024.02.006","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T20:36:17Z","timestamp":1708461377000},"page":"329-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alemtuzumab and autoimmune polyglandular syndrome with type 1 diabetes mellitus"],"prefix":"10.1016","volume":"40","author":[{"given":"D.A.","family":"Garc\u00eda Est\u00e9vez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Pinal Osorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pato Pato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2024.02.006_bib0005","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"The CAMMS223 Trial Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2024.02.006_bib0010","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":"Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort","volume":"77","author":"Cossburn","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2024.02.006_bib0015","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1007\/s00415-020-09983-1","article-title":"Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223","volume":"267","author":"Steingo","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2024.02.006_bib0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.msard.2018.10.015","article-title":"Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration","volume":"27","author":"Hoffman","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.nrleng.2024.02.006_bib0025","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1007\/s00415-014-7448-y","article-title":"First reported case of diabetes mellitus type 1 as a posible secondary autoimmune disease following alemtuzumab treatment in MS","volume":"261","author":"Malmestr\u00f6m","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2024.02.006_bib0030","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00415-019-09257-5","article-title":"Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease","volume":"266","author":"Richter","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2024.02.006_bib0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes","volume":"200","author":"Quandt","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.nrleng.2024.02.006_bib0040","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(02)08431-3","article-title":"Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study","volume":"359","author":"Marrosu","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.nrleng.2024.02.006_bib0045","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.2337\/dc06-0811","article-title":"Prevalence of diabetes in patients with multiple sclerosis","volume":"29","author":"Hussein","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.nrleng.2024.02.006_bib0050","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s40618-022-01994-1","article-title":"Type 3 autoimmune polyglandular syndrome (APS-3) or type 3 multiple autoimmune syndrome (MAS-3): an expanding Galaxy","volume":"46","author":"Betterle","year":"2023","journal-title":"J Endocrinol Invest"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580824000440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580824000440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T11:07:18Z","timestamp":1745406438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580824000440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2173580824000440"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2024.02.006","relation":{},"ISSN":["2173-5808"],"issn-type":[{"type":"print","value":"2173-5808"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alemtuzumab and autoimmune polyglandular syndrome with type 1 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2024.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2023.07.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}